Alendronate treatment for fibrous dysplasia, a rare skeletal disorder
A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of BoneJ Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
40 patients (24 adults and 16 children) with fibrous dysplasia (FD) were randomized to either receive alendronate administration in 6-month cycles for 24 months or placebo. The results revealed that in the alendronate group, NTX-telopeptides markers significantly declined at 18 months, however no significant difference in osteocalcin was observed between groups. Furthermore, areal bone mineral den...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue